Sudeep Pharma Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
- Paid Up Capital ₹ 1.41 Cr
- Company Age 35 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 132.19 Cr
- Satisfied Charges ₹ 21.21 Cr
- Revenue Growth 59.33%
- Profit Growth 49.50%
- Ebitda 48.92%
- Net Worth 45.12%
- Total Assets 55.82%
About Sudeep Pharma
Sudeep Pharma Private Limited (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 21 December 1989 and has a history of 35 years and two months. Its registered office is in Vadodara, Gujarat, India.
The Corporate was formerly known as Sudeep Pharma Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 1.41 Cr.
The company currently has active open charges totaling ₹132.19 Cr. The company has closed loans amounting to ₹21.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shanil Bhayani, Sujit Bhayani, Nils Gersonde, and One other member serve as directors at the Company.
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ1989PTC013141
- Company No.
013141
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 1989
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Sudeep Pharma Private Limited offer?
Sudeep Pharma Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Inorganic Salts, Flavours & Aromatics, Bakery & Confectionery Flavors, Industrial Chemicals & Supplies, Industrial Chemicals, Food Additive, Organic Salt, Dyes & Color Additives, White Pigments.
Who are the key members and board of directors at Sudeep Pharma?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sujit Bhayani ![]() | Managing Director | 01-Mar-1995 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Shanil Bhayani ![]() | Whole-Time Director | 10-Dec-2021 | Current |
Nils Gersonde ![]() | Director | 26-Oct-2015 | Current |
Dr Hempe ![]() | Director | 26-Oct-2015 | Current |
Financial Performance of Sudeep Pharma.
Sudeep Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 59.33% increase. The company also saw a substantial improvement in profitability, with a 49.5% increase in profit. The company's net worth Soared by an impressive increase of 45.12%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Sudeep Pharma?
In 2023, Sudeep Pharma had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹132.19 Cr
₹21.21 Cr
Charges Breakdown by Lending Institutions
- Citi Bank N.A. : 71.50 Cr
- Others : 60.69 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
29 Jan 2022 | Others | ₹60.69 Cr | Open |
29 Sep 2020 | Citi Bank N.A. | ₹20.00 Cr | Open |
20 Aug 2019 | Citi Bank N.A. | ₹6.50 Cr | Open |
27 Jan 2014 | Citi Bank N.A. | ₹45.00 Cr | Open |
02 Nov 2013 | Bank Of Baroda | ₹0.62 M | Satisfied |
How Many Employees Work at Sudeep Pharma?
Sudeep Pharma has a workforce of 377 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Sudeep Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sudeep Pharma's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.